NASDAQ$BBIO
Bridgebio Pharma Inc · Q3 2022 earnings
Q3 2022 earnings · · Investor relations
Briefing
BridgeBio reported its Q3 2022 financial results and business update, highlighting pipeline progress and expense reduction.
BridgeBio Pharma reported a decrease in operating expenses by 15.9% compared to Q2 2022, alongside positive data updates for its LGMD2i and KRAS programs. The company ended the quarter with $558.3 million in cash, providing financial runway into 2024.
- Reported positive preclinical data for KRASG12C GTP/GDP dual inhibitor development candidate, BBO-8520, and for its novel PI3Kα:RAS breaker mechanism.
- Reported positive updated 12-month Phase 2 data for BBP-418 in Limb-Girdle Muscular Dystrophy Type 2i.
- Reported dosing of first lung cancer patient in Phase 1/2 trial of SHP2 inhibitor BBP-398 in combination with Amgen’s Lumakras (sotorasib).
- Ended quarter with $558.3 million in cash, cash equivalents and marketable securities, providing financial runway into 2024.
Headline financials
Revenue & EPS history
Bridgebio · Revenue · Quarterly
$338K
Revenue by segment
Bridgebio · $100K total across 1 segment · Q2 2023
- License and Services Revenue$100K—100.0%
Forward guidance
BridgeBio anticipates continued decline in cash burn in Q4 due to potential business development and restructuring activities, expecting cash runway into 2024.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q3 2022
+1.5%
Avg return
Earnings day
+0.6%
Avg return
5 days after
+4.3%
Avg return
30 days after
48%
13 / 27 earnings
Positive
+40.9%
Q2 2022
Best reaction
-21.9%
Q1 2022
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -1.0% | -3.2% | -0.7% | |
| Q4 2025 | -2.8% | -4.1% | +2.0% | |
| Q3 2025 | -4.9% | -7.9% | +8.1% | |
| Q1 2025 | +5.3% | +4.9% | -6.0% | |
| Q4 2024 | +1.4% | -5.3% | -4.2% | |
| Q3 2024 | -5.1% | -9.2% | +5.9% | |
| Q2 2024 | +0.9% | -4.2% | +7.3% | |
| Q1 2024 | +3.0% | +2.8% | +3.6% | |
| Q4 2023 | -0.5% | +4.6% | -13.4% | |
| Q3 2023 | +8.2% | +10.3% | +16.1% | |
| Q2 2023 | -2.3% | +0.8% | -4.4% | |
| Q1 2023 | -5.0% | -4.4% | -1.0% | |
| Q4 2022 | -4.7% | -6.6% | +21.8% | |
| Q3 2022 | -1.1% | -7.0% | -4.8% | |
| Q2 2022 | +40.9% | +39.7% | +26.7% | |
| Q1 2022 | -21.9% | -29.5% | -15.9% | |
| Q4 2021 | +7.6% | +13.9% | +41.1% | |
| Q3 2021 | +6.8% | +2.0% | -22.8% | |
| Q2 2021 | +2.4% | -1.1% | -2.3% | |
| Q1 2021 | -9.3% | -7.2% | +9.5% | |
| Q4 2020 | +4.9% | -1.8% | -9.8% | |
| Q3 2020 | -1.6% | +0.3% | +30.4% | |
| Q2 2020 | +1.4% | +0.2% | +16.2% | |
| Q1 2020 | -6.8% | +6.1% | -12.7% | |
| Q4 2019 | +2.2% | -9.3% | -21.3% | |
| Q3 2019 | +22.1% | +26.2% | +49.0% | |
| Q2 2019 | +0.0% | +4.8% | -3.2% | |
| Q1 2019 | — | — | — | |
| Q4 2018 | — | — | — | |
| Q3 2018 | — | — | — | |
| Q2 2018 | — | — | — | |
| Q1 2018 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro